Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli…
Metabolic Disorders
-
-
Skye and Arecor to develop higher formulation of CB1 inhibitor
Skye Bioscience has partnered with Arecor Therapeutics to develop a higher formulation of the former’s obesity candidate nimacimab, a cannabinoid receptor…
-
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies
As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration and licencing deal worth…
-
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire…
-
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster…
-
FDA accepts Novo Nordisk’s NDA submission for weight management therapy
The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg…
-
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand…
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a…
-
FDA free to pursue semaglutide compounders after latest court ruling
A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo…
-
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide,…
